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Abstract Chromosome 11p15.5 harbors a gene or genes 
involved in Beckwith-Wiedemann syndrome that confer(s) 
susceptibility to Wilms' tumor, rhabdomyosarcoma, nd hepato- 
blastoma. We have previously identified a transcript at 1 lp15.5 
which encodes a putative membrane transport protein, designated 
organic cation transporter-like 2 (ORCTL2), that shares 
homology with tetracycline resistance proteins and bacterial 
multidrug resistance proteins. In this report, we have investigated 
the transport properties of ORCTL2 and show that this protein 
can confer resistance to ehloroquine and quinidine when 
overexpressed in bacteria. Immunohistochemistry analyses per- 
formed with anti-ORCTL2 polycional antibodies on human renal 
sections indicate that ORCTL2 is localized on the apical 
membrane surface of the proximal tubules. These results suggest 
that ORCTL2 may play a role in the transport of chloroquine 
and quinidine related compounds in the kidney. 
© 1998 Federation of European Biochemical Societies. 
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1. Introduction 
Beckwith-Wiedemann syndrome (BWS) is a congenital 
overgrowth syndrome, with a birth incidence of 1 in 13 700, 
and characterized by macroglossia, exomphalos, visceromega- 
ly, hemihypertropy, gigantism, and a predisposition to early 
childhood cancers including Wilms' tumor, rhabdomyosarco- 
ma, adrenocortical carcinoma, and hepatoblastoma [1,2]. The 
gene(s) responsible for BWS map to 11p15.5, as determined 
by linkage analysis of autosomal dominant pedigrees [3,4]. 
The complexity of the genetics of this disease is underscored 
by the description of distinct regions to which chromosomal 
breakpoints in BWS individuals have been mapped [5,6], as 
well as a maternal inheritance associated with familial cases 
suggesting a role for genomic imprinting. The identification of 
a number of imprinted genes at 11p15.5 has led to the postu- 
lation that disruption of imprinting (e.g. by chromosome 
translocation) could contribute to aberrant expression of a 
number of genes from this region [7 9]. 
In an effort to identify genes at 1 lpl5.5 that may contribute 
to the etiology of BWS, we and others have reported on the 
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isolation of a transcript which encodes for a putative mem- 
brane associated protein, called organic cation transporter- 
like 2 (ORCTL2) [10]. This gene has also been referred to 
as BWRIA [11] and IMPTI [12]. The product of ORCTL2 
shows homology to a family of proteins which have been 
studied as drug efftux pumps in bacteria, such as the multi- 
drug resistance protein of Bacillus subtilis (BMR) and the 
tetracycline (tet) transporter of Escherichia coli [10]. The ho- 
mology of ORCTL2 to bacterial polyspecific cation transport- 
ers, as well as its high expression level in the kidney (as well as 
liver and colon), suggested to us that it may play a role in 
cation transport in these organs. 
Small organic molecules, including glucose, amino acids, 
and many drugs, are transported at the proximal tubules of 
the mammalian kidney. Polyspecific organic cation transport- 
ers located at the apical and basolateral surfaces of renal 
epithelial cells mediate kinetically distinct excretion of several 
endogenous and exogenous compounds [13]. The mechanisms 
of organic cation transport across the brush border and the 
basolateral membrane have generally been studied using the 
model compound tetraethylammonium and these studies have 
shown that organic cation transport across the apical cell 
membrane occurs by an electroneutral proton/organic cation 
exchange. Recently, several of the responsible organic cation 
transporters have been cloned. A polyspecific transport pro- 
tein, OCTI [14], encodes a 1.8 kb mRNA and has the proper- 
ties of a basolateral membrane organic cation transporter. 
OCT1 is involved in the transport of organic cations from 
the blood into epithelial cells, the first step in cation excretion. 
When expressed in Xenopus laev& oocytes, OCT I mediates the 
electrogenic (NaC1)-independent and pH-independent uptake 
of a variety of endogenous cations such as choline, spermine, 
spermidine and of cationic drugs such as quinidine, quinine, 
and d-tubocurarine. 
Schwienbacher t al. [11] have recently described two muta- 
tions associated with this gene one in a breast cancer cell 
line predicted to cause premature termination of translation 
and a missense mutation in a rhabdomyosarcoma cell line, 
implying a potential role for ORCTL2 in tumor progression. 
Given the complex genetics of BWS, an understanding of the 
functional properties of genes from 11p15.5 could help in 
providing insight into the role played by some of these in 
contributing to the variety of phenotypes associated with 
this disorder. In this report, we investigate the functional 
properties of ORCTL2 and report on its distribution within 
the adult kidney. Localization of ORCTL2 suggests a role in 
transport of cation metabolites along the brush border of the 
epithelial cells of the proximal renal tubules. 
All rights reserved. 
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2. Materials and methods 
2.1. Materials 
Quinidine, chloroquine, rhodamine 6G, tetraphenylarsonium chlo- 
ride, puromycin, tetracycline and protease inhibitors were all pur- 
chased from Sigma. Molecular biology supplies were purchased 
from indicated manufacturers. 
2.2. Recombinant plasmids 
The bacterial expression vector pT7-50RCTL2 used in bacterial 
survival assays was generated from pT7-5 LacY, which has been pre- 
viously described [15]. pT7-5 LacY was digested with BamHI and 
HindIII to remove the LacY gene while not disrupting the pro- 
moter/operator elements of the lac operon. PCR amplification was 
performed on ORCTL2 using primers D7-BamHI ATG (5'-CGGG- 
ATCCATGCAGGGAGCTCGGACT-Y) and D7-YH(AS) (5'-CGG- 
GATCCCGTCACCGGACTTTGTCCTT-Y). Because D7-BamHI 
ATG contains a BamHI site immediately upstream of the ATG codon 
(underlined in the sequence), this manipulation placed the ORCTL2 
ATG codon in the same context and position (relative to the Shine- 
Dalgarno sequence) as it was for LacY. The PCR product was di- 
gested with BamHI and Pstl and was ligated to a 3' truncated 
ORCTL2 cDNA insert which had been generated by digesting 
ORCTL2 with PstI and HindIII. Subsequently, a three way ligation 
was performed to create pT7-50RCTL2, which places the ORCTL2 
cDNA under IPTG inducibility. 
For transient transfections tudies in COS-7 cells, wild-type 
ORCTL2 and hemagglutinin tagged (HA) ORCTL2 cDNA was 
cloned into the eukaryotic expression vector, pcDNA3. The plasmid, 
pcDNA3/ORCTL2, was created by placing the BamHIlEcoRI 
ORCTL2 cDNA (nucleotides -120 to +1333) into BamHI/EcoRI 
digested pcDNA3 using T4 DNA ligase, pcDNA3/(HA)ORCTL2 
contains an HA tag introduced between the native ATG codon and 
the second codon of ORCTL2 and was created by replacing a small 
portion of the ORCTL2 amino-terminal domain with oligonucleotides 
designed to incorporate the HA epitope sequences. Oligonucleotides 
used for these experiments were D7 5'HA (s) (5'-CGGGGTACCC- 
CCCAGGATGTACCCCTACGACGTCCCCGACTACGCCTCCC- 
TGCAGGGAGCT-3') and D7 5'HA (as): (5'-CCCTGCAGGGA- 
GGCGTAGTCGGGGACGTCGTAGGGGTACATCCTGGGGG- 
GTACCCCGAGCT-3') which, once annealed, were ligated into a 
Sacl site at position +12 of the ORCTL2 cDNA. The HA tagged 
cDNA was then digested with KpnI (present at position -5) and 
EeoRI, the insert gel-purified, and ligated into pcDNA3 digested 
with the same restriction enzymes, pcDNA3/ORCTL2 (HA) contains 
nucleotides -120 to +1272 of the ORCTL2 cDNA with an HA tag 
juxtaposed next to the stop codon. The 3' HA tag was introduced into 
ORCTL2 by PCR amplification using oligonucleotide primers: D7 
YHA (5'-GGGGTACCCCTCACAGGGAGGCGTAGTCGGGGA- 
CGTCGTAGGGGTACCGGACTTTGTCCTTCC-Y) and D7-1 (5'- 
GTCACCGACAGCATGCTG-3') which amplified a 240 bp fragment 
of DNA between nucleotides +1042 and +1272 of the ORCTL2 
cDNA, introducing an HA tag and a BamH1 site at the 3' end of 
ORCTL2. This PCR fragment was then digested with SphI (located at 
nucleotide +1178 of ORCTL2) and BamH1 and ligated into pcDNA3/ 
ORCTL2 which had been digested with the same enzymes. All PCR 
amplification products were sequenced by the chain termination meth- 
od to ensure the absence of unwanted mutations. The plasmid, pT7-5 
Mdrl, has been previously described and contains the murine multi- 
drug resistance protein (P-glycoprotein) under control of the lac op- 
eron [16]. 
2.3. Generation of ORCTL2-specific antibodies 
ORCTL2-specific antibodies were generated by injecting New Zea- 
land White rabbits with a 10 amino acid peptide, NH3-LLVLWRK- 
PMPQRKDKVR-COOH, corresponding to the last 10 carboxy-ter- 
minal amino acids of ORCTL2. Initial injections were performed with 
350 lag of peptide in Freund's complete adjuvant and subsequent 
boosts were performed with 200 p_g of peptide in Freund's incomplete 
adjuvant every 3 weeks. Peptide-specific antibodies were purified from 
the antisera using an affinity matrix generated by covalently linking 
the immunogen on an azlactone activated support (UltraLink Immo- 
bilized Carboxy, Pierce). Following incubation of serum with the 
coupled peptide, the column was washed, and peptide-specific anti- 
bodies were eluted using 4 M urea and dialyzed overnight against 
PBS. 
2.4. Bacterial resistance assay 
The bacterial resistance assay was performed using UTL2, a UV 
irradiated mutant of E. coli UT5600 (OmpT) that is sensitive to 
many cytotoxic drugs [16]. Resistance of UTL2 E. coli cells harboring 
pT7-5 LacY, pT7-5 Mdrl of pT7-50CTR against various com- 
pounds was assayed in liquid medium. Cells harboring the appropri- 
ate plasmids were grown at 30°C in Luria broth (LB) supplemented 
with 100 lag ampicillin per ml. Overnight cultures were diluted 1:50 
and grown to an ODes00 =0.6. Cells were then diluted and aliquoted 
(50 ~1) into 96 well microplates containing 50 pA of the indicated 
concentrations of drugs and 0.1 mM IPTG. Plates were incubated 
in a 30°C shaker, and the OD6~II I was measured every 4 h for 16- 
20 h using a microplate reader. In experiments with chloroquine 
and quinidine, LB medium was supplemented with 60 mM Bis-Tris- 
propane to maintain the pH at 7.4. 
2.5. Cell culture, transJections, and membrane preparations 
COS-7 cells were maintained in Dulbecco's modified Eagle's me- 
dium supplemented with 10% fetal calf serum (Gibco BRL), penicillin 
(50 units/ml) and streptomycin (50 ~tg/ml) (Gibco BRL). For transient 
transfections, cells were seeded at a density of 2-5× 105 cells per 100 
mm plate one day prior to transfection. Cells were transfected using 
the calcium phosphate precipitation method [17]. For individual trans- 
fections, 12.5 lag of plasmid DNA was used and cells were harvested 
48 h later. 
After transient ransfections, cells were harvested with a rubber 
policeman in cold PBS (phosphate buffered saline) containing 20 
mM sodium citrate but lacking magnesium and calcium. Cells were 
collected in 15 ml conical tubes (Falcon) by centrifugation at 
~800×g for 5 rain, resuspended in Tris-Mg buffer (10 mM Tris 
[pH 7.0], 5 mM MgCI2) supplemented with the protease inhibitors 
leupeptin (1 [,tg/ml), aprotinin (2 I.tg/ml), and antipain (1 ~g/ml). Cells 
were then subjected to Dounce (type A) homogenization a d nuclei 
were eliminated by centrifugation in a clinical centrifuge at ~ 1000 × g 
for 5 min. Cellular membranes from the supernatant were collected by 
ultracentrifugation n an SW40 rotor (Beckman) for 30 rain at 20000 
rpm. The membrane pellet was resuspended in TNE buffer (100 mM 
NaCI, 10 mM Tris [pH 7.0], 10 mM EDTA) containing 30% glycerol 
and protease inhibitors. These preparations were stored at -80°C 
until ready to use. 
2.6. h~mmnofluorescenee of r nal sections using anti-ORCTL2 
antibodies 
Tissue from fetal kidneys (age 22 weeks) was stored at -70°C with- 
out further fixation. Sections (7 10 ~tm thickness) from tissues were 
cut with a cryostat, transferred onto glass slides, and fixed overnight 
at -20°C in methanol with 0.5% EGTA. Endogenous tissue was 
preblocked with PBS/methanol/H202 (59.5%/40%10.5%) for 20 min 
at room temperature. After two washing steps in H20 and one rinse 
in PBS, the section was buffered for 30 rain in PBS/normal goat serum 
(10:1) at room temperature in a humid chamber. After this, the af- 
finity purified antibody against ORCTL2 was applied to different 
sections in different dilutions ranging from 1:10 to 1:1000 and incu- 
bated in a humidified chamber overnight at 4°C. The tissue sections 
were washed three times with PBS and then overlaid with biotinylated 
anti-rabbit antibody diluted in PBS (1:100) for 30 min. This incuba- 
tion was again followed by washing sections in PBS, after which the 
peroxidase r action was performed for 20 min using the ABC Immu- 
nostain solution and visualized with a diaminobenzidine tetrahydro- 
chloride solution (1 mg/ml) containing 0.01% H202 for 30 s to 4 rain 
(Santa Cruz ABC Immunostain Systems). The staining reaction was 
stopped by immersing slides into distilled water, followed by a short 
counterstaining in hematoxylin. Tissue sections were dehydrated by 
rinsing in a series of washes with increasing ethanol concentrations 
(70 100%), washing in xylene, and mounting with Permount medium. 
3. Results and discussion 
Analysis of genes within a 1 Mbp PAC contig at human 
chromosome 11 band p15.5 identified an expressed sequence 
tag (EST) showing homology to organic cation transporters 
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Fig. 1. Resistance of 1:2 coli UTL-2 to chloroquine (A), quinidine (B), rhodamine 6G (C) and tetracycline (D). E. coli UTL-2 harboring either 
pTT-5 LacY, pT7-50RCTL2, or pT7-5 Mdrl was grown in the presence of increasing concentrations of drug and the growth rates were moni- 
tored by measuring the OD~;00, as indicated in Section 2. Relative growth is plotted as a function of drug concentration. Experiments were 
done in duplicate with three different bacterial colonies each time. 
[10]. The gene corresponding to this EST was subsequently 
named ORCTL2 (organic cation transporter-like 2), BWR1A 
[11], or IMPT1 [13]. ORCTL2 shows highest homology with 
the E. coli tetA class E tetracycline resistance protein and the 
multidrug resistance protein 2 of B. subtilis [10], consistent 
with the idea that ORCTL2 is a membrane pump involved 
in cellular detoxification. 
3.1. Transport properties of  ORCTL2 
Tetracycline resistance in bacteria is conferred by three bio- 
chemically distinct mechanisms: (i) energy-dependent active 
efflux of tetracycline, (ii) ribosome protection, and (iii) tetra- 
cycline modification. Tetracycline resistance genes have been 
grouped into 12 classes based on their failure to cross-hybrid- 
ize under stringent conditions [18,19]. In Gram-negative bac- 
teria, the outer membrane xhibits a strong permeability bar- 
rier to many lipophilic compounds and the primary 
mechanism of tetracycline resistance is based on active efflux 
of the drug [20]. These tetracycline extrusion molecules, such 
as tetA, belong to the large major facilitator family of mem- 
brane translocases [21,22] and mediate resistance by acting as 
a tetracycline/H + antiporters, exporting a tetracycline-divalent 
cation complex in exchange for a proton. 
To elucidate a functional role of ORCTL2 as a transport 
protein, we employed a recently described bacterial-based 
growth assay [16]. Generally, wild-type E. coli cells are insen- 
sitive to most cancer and organic cation-like cytotoxic om- 
pounds because of the outer membrane permeability barrier. 
However, E. coil UTL2, a UV irradiation derived mutant of 
UT5600 (ompT) ,  have a permeable outer membrane and are 
sensitive to the growth inhibitory effects of rhodamine 6G, 
daunomycin, puromycin, quinidine, and chloroquine [16]. 
The drug sensitivity profile of UTL2, transfected with pT7-5 
LacY, a prokaryotic expression vector driving synthesis of 
LacY, is unchanged (Fig. 1). Chloroquine, quinidine, and 
rhodamine 6G are inhibitory to growth of this strain (Fig. 
I A C). In addition, this strain is also sensitive to tetracycline 
(Fig. ID). As previously reported [16], when the murine P- 
glycoprotein gene is expressed in UTL2, the bacteria re pro- 
tected against he cytotoxic effects of chloroquine, quinidine, 
and rhodamine 6G (Fig. 1A-C). We also find that P-glyco- 
protein can provide resistance to tetracycline as well (Fig. 
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Fig. 2. Western blot analysis of ORCTL2 and HA (hemagglutinin) 
tagged ORCTL2 in membrane preparations of transfected COS-7 
cells. Membrane fractions were prepared from carboxy-terminal HA 
tagged ORCTL2 (C.T.-HA ORCTL2), amino-terminal HA tagged 
(N.T.-HA ORCTL2), wild-type ORCTL2, and pcDNA3 alone 
transfected COS-7 cells as described in Section 2. 40 Jag of protein 
was fractionated on a 10% SDS-PAGE. Proteins were transferred to 
lmmobilon-P (Millipore) and probed with (A) 12CA5, an anti-HA 
epitope monoclonal antibody or (B) affinity purified anti-ORCTL2 
polyclonal antibodies. The antibody-antigen complex was detected 
using the ECL chemiluminescense (NEN) detection system. 
I D). When ORCTL2 was assayed in this heterologous expres- 
sion system, robust resistance to chloroquine was observed 
(Fig. 1A) and weak resistance to quinidine was noticed (Fig. 
I B), but no protective ffect against either hodamine 6G (Fig. 
IC) or tetracycline (Fig. 1D) was observed. Also, ORCTL2 
could not protect against either tetraphenylarsonium (TPA) 
or puromycin (data not shown), two other drugs which 
mdrl has been shown to confer resistance to [16]. 
We attribute the ability of ORCTL2 to confer resistance to 
chloroquine (and partially to quinidine) as being due to the 
predicted transport properties of this molecule. It is somewhat 
surprising that ORCTL2 cannot confer resistance to tetracy- 
cline, considering the homology of ORCTL2 and the E. coli 
tetracycline resistance proteins. However, this may reflect the 
tact that primary protein sequence homology cannot be accu- 
rately used to define transport specificity. A case in point is 
the sequence comparison of QacA/B, two very similar proteins 
associated with resistance to antiseptics and disinfectants; 
Mmr, a resistance gene for the antibiotic methylenomycin 
A; and Tet(K) and Tet(L), the tetracycline fflux protein of 
Gram-negative bacteria. In this case, Tet(L) and Tet(K) show 
a lower degree of homology to the tetracycline r sistance pro- 
teins of Gram-negative bacteria than do QacA/B and Mmr, 
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yet they transport etracycline and QacA/B and Mmr do not 
[23]. Our UTL2 growth experiments are suggestive of a trans- 
port function for ORCTL2 in handling chloroquine and/or 
quinidine related compounds. 
3.2. Localization ~[' ORCTL2 in the kidney 
To determine the tissue and cellular distribution of 
ORCTL2, we raised polyclonal antibodies to a peptide de- 
rived from the carboxy-terminal sequence of ORCTL2. The 
ability of our antibodies to specifically recognize ORCTL2 
was assessed by Western blot analysis (Fig. 2). Transfections 
in COS-7 cells were performed with either the empty expres- 
sion cassette, pcDNA3, or pcDNA3 driving the synthesis of: 
(i) carboxy-terminal (C.T.) HA tagged ORCTL2, (ii) amino- 
terminal (N,T.) HA tagged ORCTL2, or (iii) wild-type 
ORCTL2. Membrane preparations from transfected cells 
were fractionated by SDS-PAGE, transferred to nitrocellulose 
membrane, and processed for Western blotting. Probing with 
anti-HA antibodies demonstrated that extracts from both 
N.T.-HA tagged and C.T.-HA tagged ORCTL2 transfected 
cells contained a novel protein migrating with a molecular 
mass of ,-~40 kDa (Fig. 2A). Probing with our anti-peptide 
antibody detected a protein of similar molecular mass in N.T.- 
HA tagged and C.T.-HA tagged ORCTL2 transfected cells, as 
well as in cells transfected with pcDNA/ORCTL2 (Fig. 2B). 
In these experiments, ORCTL2 migrates with an apparent 
molecular mass of ,~40 kDa, although the predicted molec- 
ular mass is 48.8 kDa [10]. The reason(s) for this discrepancy 
is not understood, but it is clear that since the amino-terminal 
and carboxy-terminal HA tagged protein are synthesized, this 
difference in size is not due to alternative translation initiation 
at an internal ATG codon. 
Immunohistochemical analysis of ORCTL2 was performed 
on sections of human fetal kidneys. Background staining was 
minimal when the specific anti-ORCTL2 antibody was omit- 
ted from the section (Fig. 3A). A survey of the renal periph- 
eral and central structures clearly shows ORCTL2 staining at 
some glomeruli and the proximal parts of the tubules (Fig. 
3B). The more differentiated glomeruli (found deeper in the 
cortex) display a lower degree of staining than their less differ- 
entiated counterparts, possibly reflecting a developmentally 
regulated phenomenon. ORCTL2 does not appear to be sig- 
nificantly expressed in the distal tubules (Fig. 3B). A higher 
magnification reveals that ORCTL2 is also present at the 
transition between the glomerulus and the tubules (Fig. 
3C,E). This expression site suggests that ORCTL2 may be 
involved in transporting compounds into or from the primary 
filtrate. These experiments also revealed that ORCTL2 is lo- 
calized to the apical membrane surface of the epithelial cells 
of the proximal renal tubules (Fig. 3D). 
The renal proximal tubules are a major site of excretion of 
many xenobiotics and endogenous compounds, either directly 
or after metabolic transformation. These compound are trans- 
ported mainly by organic cation or organic anion transport 
systems and recently, several such transporters have been 
cloned and shown to be expressed in the kidney. One such 
protein, considered to represent a new class of cation-specific 
transporters, is OCTI [14]. OCTI and a related protein OCT2 
are both expressed in the proximal tubules of the kidney and 
can transport wo prototypical organic cations, tetraethylam- 
monium (TEA) and N-methylnicotinamide (NMN). Another 
OCT l-related transporter, OAT-I, is expressed almost exclu- 
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Fig. 3. lmmunohistochemical detection of ORCTL2 in human fetal kidney sections (22 weeks old) using affinity purified anti-ORCTL2 polyclo- 
nal antibodies. A: Negative control staining (no anti-ORCTL2 antibody added). B: Survey of the kidney showing staining of ORCTL2 in pe- 
ripheral and central renal structures. C: Staining of ORCTL2 at the transition of the glomerulus into the tubules. D: Staining of ORCTL2 to 
the apical membrane surface of the proximal tubules. E: Staining of ORCTL2 at the glomerular loop and within the proximal tubules. 
sively in the kidney, and has been shown to transport para- 
aminohippurate in a Na+-independent manner, and may be 
an organic anion/decarboxylate exchanger at the basolateral 
membrane of the proximal tubules [24]. There are a number of 
organic anion transporters that have been cloned and, given 
that some are also expressed in the kidney, they may have a 
role in renal transport. These include MRPI (multidrug resist- 
ance-associated protein 1) and its homologues MRP2, MRP3, 
MRP4, and MRP5 [25]. MRP2, or cMOAT, is expressed in 
the apical membrane surface of the renal proximal tubules 
and is capable of conferring the multidrug resistance pheno- 
type to some cell lines [14,25]. The multidrug-specific P-glyco- 
protein (MDR1) is also expressed in the apical membrane 
surface of the renal proximal tubules [26]. 
ORCTL2 represents a new class of mammalian transporters 
located at the renal proximal tubules, that may transport or- 
ganic cations based on a proton efflux antiport mechanism 
similar to the mechanism used by the tetracycline fflux pro- 
teins. Given that this gene resides in the Beckwith-Wiedemann 
syndrome critical region (BWSCR) at 11p15.5, it is interesting 
to speculate on a possible role for ORCTL2 in the etiology of 
this disease and of associated malignancies. Schwienbacher t
al. [II] have identified two cell lines with mutations in 
ORCTL2 a breast cancer cell line (BT549) with an insertion 
causing premature termination and a rhabdomyosarcoma cell 
line (TEI25-T) with a missense mutation at one ORCTL2 
(converting a His residue to an Arg) allele. Clearly additional 
work is needed to imply a significant role for ORCTL2 in the 
progression of cancer but should one of the compounds trans- 
ported by ORCTL2 prove to be a genotoxic agent, then one 
could envisage a model whereby inactivating ORCTL2 muta- 
tions lead to increased intracellular concentrations of the gen- 
otoxic agent, resulting in increased frequency of genetic le- 
sions. 
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